THE FUTURE OF HEART FAILURE MANAGEMENT: EMERGING THERAPIES AND TECHNOLOGIES

Background: Heart failure (HF) While traditional treatments are still a major worldwide burden for mortality and morbidity, innovative treatment and diagnosis methods are urgently needed. Conventional therapies, as applied in the conventional medical model, though able to provide symptomatic relief, are often unable to reverse the disease process, let alone slow it in the worst-case scenario. Objective: Through this systematic review, the effectiveness, safety, and clinical relevance of advanced pharmacological, medical device, and point-of-care technologies for effectively managing heart failure will be assessed. Methods: To supplement the literature review, an electronic search was conducted in Pubmed, Cochrane Database, and Scopus with data collected from the past decade regarding PRISMA guidelines. Regarding inclusion criteria, systematic review and meta-analysis studies build on randomized controlled trials, prospective and retrospective cohort studies, case-control studies, and systematic reviews of novel pharmacological treatments, innovative and sophisticated device-based therapy, and novel diagnostics. Results: The new pharmacological agents, the SGLT2 inhibitors, and the ARNi particularly, were shown to have reduced hospitalization and mortality rates as was noticeable from conventional therapies. Technology-based therapies such as CRT, ICD, LVAD, and wearable technology gave patients better chances of survival, better quality of life, and a better opportunity for additional monitoring, especially for those with advanced HF. New technology like biomarkers, cardiac MRI, and innovative, AI-based tools offered essential findings and high sensitivity and specificity of diagnosis and risk assessment. Conclusion: The study implies that new commodity therapies and technologies carry a future capacity in heart failure. SGLT2 inhibitors, ARNi, CRT, ICDs, and advanced diagnostic methods make HF management more individualized and effective by providing patient-centered increases in outcomes, quality of life, and efficiency of available resources.